SCHEMBL2919151

SCHEMBL2919151

O=C(NCCc1ccccc1)c1ccc(O)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC2 Q92769 1/20 0.76
HDAC8 Q9BY41 1/20 0.76
HDAC6 Q9UBN7 1/20 0.76
RAB9A P51151 9/20 0.73
NPC1 O15118 8/20 0.73
SMN1; SMN2 Q16637 4/20 0.71
MAPT P10636 2/20 0.71
CYP1A2 P05177 1/20 0.71
GAA P10253 1/20 0.71
CYP2D6 P10635 1/20 0.71
CYP2C19 P33261 1/20 0.71
GFER P55789 1/20 0.71
ESRRG P62508 3/20 0.68
MLYCD O95822 2/20 0.68
ESRRB O95718 2/20 0.68
MEN1 O00255 1/20 0.66
KMT2A Q03164 1/20 0.66
TAAR1 Q96RJ0 1/20 0.66
SYK P43405 1/20 0.64
HSD17B10 Q99714 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5594655 0.93 RAB9A (0.71) HDAC2HDAC8HDAC6RAB9ANPC1
SCHEMBL31420450 0.91 NPC1 (0.84) HDAC2HDAC8HDAC6RAB9ANPC1
SCHEMBL14302481 0.91 MEN1 (0.69) HDAC2HDAC8HDAC6RAB9ANPC1
SCHEMBL751214 0.89 HDAC2 (0.80) HDAC2HDAC8HDAC6RAB9ANPC1
SCHEMBL11711200 0.89 RAB9A (0.66) HDAC2HDAC8HDAC6RAB9ANPC1
SCHEMBL14302482 0.88 RAB9A (0.65) HDAC2HDAC8HDAC6RAB9ANPC1
SCHEMBL7282271 0.88 HDAC2 (0.78) HDAC2HDAC8HDAC6RAB9ANPC1
SCHEMBL6841899 0.88 HDAC2 (0.78) HDAC2HDAC8HDAC6RAB9ANPC1
Hydrochloric Acid SCHEMBL28193721 0.87 HDAC2 (0.77) HDAC2HDAC8HDAC6RAB9ANPC1
SCHEMBL26844450 0.87 HDAC2 (0.58) HDAC2HDAC8HDAC6RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113950477-B Granulin precursor modulators and methods of use thereof 阿库达医疗公司 2024-07-05 CN disclosed
US-20220251084-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME JANSSEN PHARMACEUTICA NV (BE) 2022-08-11 US disclosed
EP-3983401-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME Arkuda Therapeutics (US) 2022-04-20 EP disclosed
WO-2020252222-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS (US) 2020-12-17 WO disclosed
WO-2020252222-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS (US) 2020-12-17 WO disclosed
EP-2222160-A2 HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR Pharmaxis Ltd. (AU) 2010-09-01 EP disclosed
WO-2009066152-A2 HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR PHARMAXIS LTD. (US) 2009-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220251084-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME GRN, PRNP, PSEN2 HDAC2 2859/4885HDAC8 2108/4885HDAC6 800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.